Browsing Tag
ASCO
9 posts
Avacta just won a clean FDA path to full AVA6000 approval, so why did $AVCT barely move?
Avacta won a clean FDA path to full AVA6000 approval, yet AVCT (AIM) barely moved. The real question is whether a partner signs before cash runs low.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
IDEAYA Biosciences (IDYA) stock in focus as ASCO 2026 late-breaker sets up fuller OptimUM-02 readout
IDEAYA Biosciences heads to ASCO 2026 with full OptimUM-02 data. Read why the late-breaking slot could matter for IDYA stock and melanoma strategy.
Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing
Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.
OMI Pulse gains ASCO recognition for oncology pathway data, setting new benchmarks in clinical quality
OMI Pulse earns ASCO recognition as a quality solution for oncology pathways, streamlining compliance and advancing value-based cancer care delivery.
Vepdegestrant delivers Phase 3 success for Arvinas and Pfizer in ESR1-mutant breast cancer
Vepdegestrant shows 43% risk reduction in ESR1-mutant breast cancer vs fulvestrant. Learn how Arvinas and Pfizer aim for FDA filing in H2 2025.
Avistone Biotechnology presents positive ASCO 2025 results for dual inhibitor therapy in EGFR-mutated NSCLC
Avistone reveals 50% ORR and 9.9-month PFS for its Vebreltinib–Andamertinib combo in MET-amplified NSCLC at ASCO 2025. Find out what this means for lung cancer care.
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their…
Dizal’s sunvozertinib shows promising results in global pivotal lung cancer study
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from…